Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/31859
Title: Mosaicism in tuberous sclerosis complex: Lowering the threshold for clinical reporting.
Austin Authors: Ye, Zimeng;Lin, Sufang;Zhao, Xia;Bennett, Mark F ;Brown, Natasha J;Wallis, Mathew J ;Gao, Xinyi;Sun, Li;Wu, Jiarui;Vedururu, Ravikiran;Witkowski, Tom ;Gardiner, Fiona;Stutterd, Chloe A ;Duan, Jing;Mullen, Saul A ;McGillivray, George;Bodek, Simon;Valente, Giulia M ;Reagan, Matthew;Yao, Yi;Li, Lin;Chen, Li;Boys, Amber;Adikari, Thiuni N;Cao, Dezhi;Hu, Zhanqi;Beshay, Victoria;Zhang, Victor W;Berkovic, Samuel F ;Scheffer, Ingrid E ;Liao, Jianxiang;Hildebrand, Michael S 
Affiliation: Epilepsy Research Centre
Department of Neurology, Epilepsy Centre, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, China.
Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.
Austin Health
AmCare Genomics Laboratory, Guangzhou, Guangdong Province, China.
Molecular Diagnostic Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Victorian Clinical Genetics Services, Royal Children's Hospital, Parkville, Victoria, Australia.
Department of Neurology, Epilepsy Centre, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, China.
Victorian Clinical Genetics Services, Royal Children's Hospital, Parkville, Victoria, Australia.
Department of Medicine, Peninsula Health, Monash University, Frankston, Victoria, Australia.
Molecular Diagnostic Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
AmCare Genomics Laboratory, Guangzhou, Guangdong Province, China.
Department of Neurology, Epilepsy Centre, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, China.
The Florey Institute of Neuroscience and Mental Health
Issue Date: Dec-2022
Date: 2022
Publication information: Human Mutation 2022; 43(12)
Abstract: Tuberous sclerosis complex (TSC) is a multi-system genetic disorder. Most patients have germline mutations in TSC1 or TSC2 but, 10%-15% patients do not have TSC1/TSC2 mutations detected on routine clinical genetic testing. We investigated the contribution of low-level mosaic TSC1/TSC2 mutations in unsolved sporadic patients and families with TSC. Thirty-one sporadic TSC patients negative on routine testing and eight families with suspected parental mosaicism were sequenced using deep panel sequencing followed by droplet digital polymerase chain reaction. Pathogenic variants were found in 22/31 (71%) unsolved sporadic patients, 16 were mosaic (median variant allele fraction [VAF] 6.8% in blood) and 6 had missed germline mutations. Parental mosaicism was detected in 5/8 families (median VAF 1% in blood). Clinical testing laboratories typically only report pathogenic variants with allele fractions above 10%. Our findings highlight the critical need to change laboratory practice by implementing higher sensitivity assays to improve diagnostic yield, inform patient management and guide reproductive counseling.
URI: https://ahro.austin.org.au/austinjspui/handle/1/31859
DOI: 10.1002/humu.24454
ORCID: 0000-0002-5578-9374
Journal: Human Mutation
Start page: 1956
End page: 1969
PubMed URL: 36030538
ISSN: 1098-1004
Type: Journal Article
Subjects: high-depth sequencing
mosaic mutations
parental mosaicism
tuberous sclerosis complex
Tuberous Sclerosis/diagnosis
Tuberous Sclerosis/genetics
Tuberous Sclerosis/pathology
Tuberous Sclerosis Complex 2 Protein/genetics
Tuberous Sclerosis Complex 1 Protein/genetics
Tumor Suppressor Proteins/genetics
Appears in Collections:Journal articles

Show full item record

Page view(s)

62
checked on Jul 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.